Man Group plc Acquires New Position in Insulet Corporation $PODD

Key Points

• Man Group acquired 517,217 Insulet shares during the second quarter, worth approximately $78.7 million and representing about 0.75% of the company. Other major institutions, including BlackRock and Norges Bank, also established or increased positions.
• Insulet’s latest quarter exceeded expectations, with EPS of $1.66 versus $1.47 expected and revenue up 23.5% year over year to $801.7 million. However, analyst sentiment is mixed: the consensus rating is “Hold,” with an average price target of $195.40, while the stock recently traded near $143.
• The company faces increased legal and reputational risk following securities class-action notices alleging manufacturing deficiencies and issues involving Omnipod device corrections or recalls. The allegations have not been proven.

Man Group plc acquired a new stake in Insulet Corporation (NASDAQ:PODD - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 517,217 shares of the medical instruments supplier's stock, valued at approximately $78,746,000. Man Group plc owned about 0.75% of Insulet as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of PODD. BlackRock Inc. acquired a new stake in shares of Insulet during the second quarter worth $1,018,582,000. Norges Bank bought a new position in Insulet during the fourth quarter worth about $300,794,000. Arrowstreet Capital Limited Partnership boosted its holdings in Insulet by 462.7% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier's stock worth $258,088,000 after buying an additional 1,011,369 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Insulet during the 2nd quarter worth about $60,615,000. Finally, Deutsche Bank AG acquired a new position in shares of Insulet during the 2nd quarter worth about $51,153,000.

Analysts Set New Price Targets

A number of brokerages recently weighed in on PODD. Citigroup increased their price target on shares of Insulet from $165.00 to $172.00 and gave the company a "neutral" rating in a research report on Wednesday, July 8th. Wells Fargo & Company downgraded shares of Insulet from an "overweight" rating to an "equal weight" rating and lowered their target price for the company from $255.00 to $144.00 in a research note on Wednesday, August 5th. The Goldman Sachs Group reaffirmed a "buy" rating and issued a $205.00 target price on shares of Insulet in a research note on Wednesday, May 27th. UBS Group cut their target price on shares of Insulet from $174.00 to $150.00 and set a "neutral" rating on the stock in a report on Thursday, August 6th. Finally, Oppenheimer cut shares of Insulet from an "outperform" rating to a "market perform" rating in a research report on Wednesday, August 5th. Fourteen research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $195.40.

Key Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet CEO Ashley McEvoy purchased 1,100 shares at an average price of $147.47, an investment of approximately $162,200. The purchase increased her direct holdings by about 5% and may signal management confidence following the stock’s substantial decline. Insulet CEO share purchase
• Positive Sentiment: Recent operating results remain a support: Insulet’s latest quarterly report exceeded analyst expectations for both earnings and revenue, with revenue rising 23.5% year over year and margins improving. The company’s growth outlook, however, has been reset, making execution key to the investment case.
• Neutral Sentiment: Reported short-interest data shows zero shares short and a zero-day short-interest ratio, but the stated month-over-month change is “NaN,” indicating the data is likely incomplete or erroneous. It should not be interpreted as evidence of a meaningful short-covering or short-selling trend.
• Negative Sentiment: Pomerantz announced that a securities class action has been filed in federal court against Insulet and certain officers. The proposed class covers investors who purchased securities from February 21, 2025, through May 26, 2026, and alleges violations of federal securities laws. The allegations have not been proven. Pomerantz class action announcement
• Negative Sentiment: Several firms issued substantially similar notices encouraging investors to seek lead-plaintiff status by August 31. The claims center on alleged manufacturing deficiencies and two voluntary corrections or recalls affecting millions of Omnipod devices, as well as assertions that Insulet overstated manufacturing quality and growth prospects. The volume of legal announcements increases reputational, litigation-cost, and potential-liability concerns, even though the notices themselves do not establish wrongdoing.

Insulet Trading Down 1.6%

Shares of NASDAQ:PODD opened at $143.05 on Wednesday. Insulet Corporation has a 12 month low of $126.40 and a 12 month high of $354.88. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65. The company's fifty day simple moving average is $154.52 and its 200 day simple moving average is $182.80. The firm has a market cap of $9.92 billion, a price-to-earnings ratio of 26.74, a PEG ratio of 1.15 and a beta of 1.10.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, beating the consensus estimate of $1.47 by $0.19. The business had revenue of $801.70 million for the quarter, compared to analysts' expectations of $787.39 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The firm's revenue was up 23.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, research analysts forecast that Insulet Corporation will post 6.51 EPS for the current fiscal year.

Insider Activity at Insulet

In other news, Director Timothy C. Stonesifer purchased 2,790 shares of the business's stock in a transaction dated Wednesday, June 3rd. The shares were bought at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the acquisition, the director directly owned 9,041 shares in the company, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.36% of the stock is currently owned by company insiders.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source